25 XP   0   0   10

Gan & Lee Pharmaceuticals Co Ltd
Buy, Hold or Sell?

Let's analyse Gan & Lee Pharmaceuticals Co Ltd together

PenkeI guess you are interested in Gan & Lee Pharmaceuticals Co Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Gan & Lee Pharmaceuticals Co Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Gan & Lee Pharmaceuticals Co Ltd

I send you an email if I find something interesting about Gan & Lee Pharmaceuticals Co Ltd.

Quick analysis of Gan & Lee Pharmaceuticals Co Ltd (30 sec.)










What can you expect buying and holding a share of Gan & Lee Pharmaceuticals Co Ltd? (30 sec.)

How much money do you get?

How much money do you get?
¥0.00
When do you have the money?
1 year
How often do you get paid?
68.8%

What is your share worth?

Current worth
¥16.65
Expected worth in 1 year
¥17.12
How sure are you?
81.3%

+ What do you gain per year?

Total Gains per Share
¥0.47
Return On Investment
0.9%

For what price can you sell your share?

Current Price per Share
¥50.04
Expected price per share
¥39.12 - ¥62.90
How sure are you?
50%

1. Valuation of Gan & Lee Pharmaceuticals Co Ltd (5 min.)




Live pricePrice per Share (EOD)

¥50.04

Intrinsic Value Per Share

¥-28.56 - ¥-34.25

Total Value Per Share

¥-11.91 - ¥-17.60

2. Growth of Gan & Lee Pharmaceuticals Co Ltd (5 min.)




Is Gan & Lee Pharmaceuticals Co Ltd growing?

Current yearPrevious yearGrowGrow %
How rich?$1.3b$1.3b-$34.9m-2.6%

How much money is Gan & Lee Pharmaceuticals Co Ltd making?

Current yearPrevious yearGrowGrow %
Making money$8.3m$5.7m$2.5m30.4%
Net Profit Margin8.9%-49.9%--

How much money comes from the company's main activities?

3. Financial Health of Gan & Lee Pharmaceuticals Co Ltd (5 min.)




4. Comparing to competitors in the Medical Instruments & Supplies industry (5 min.)




  Industry Rankings (Medical Instruments & Supplies)  


Richest
#40 / 169

Most Revenue
#55 / 169

Most Profit
#166 / 169

Most Efficient
#127 / 169

What can you expect buying and holding a share of Gan & Lee Pharmaceuticals Co Ltd? (5 min.)

Welcome investor! Gan & Lee Pharmaceuticals Co Ltd's management wants to use your money to grow the business. In return you get a share of Gan & Lee Pharmaceuticals Co Ltd.

What can you expect buying and holding a share of Gan & Lee Pharmaceuticals Co Ltd?

First you should know what it really means to hold a share of Gan & Lee Pharmaceuticals Co Ltd. And how you can make/lose money.

Speculation

The Price per Share of Gan & Lee Pharmaceuticals Co Ltd is ¥50.04. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Gan & Lee Pharmaceuticals Co Ltd.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Gan & Lee Pharmaceuticals Co Ltd, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ¥16.65. Based on the TTM, the Book Value Change Per Share is ¥0.12 per quarter. Based on the YOY, the Book Value Change Per Share is ¥0.01 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ¥0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Gan & Lee Pharmaceuticals Co Ltd.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 ¥% of Price per Share¥% of Price per Share¥% of Price per Share¥% of Price per Share¥% of Price per Share
Usd Eps0.030.1%0.020.0%0.010.0%0.040.1%0.040.1%
Usd Book Value Change Per Share0.030.1%0.020.0%0.000.0%0.140.3%0.140.3%
Usd Dividend Per Share0.000.0%0.000.0%0.030.1%0.020.0%0.020.0%
Usd Total Gains Per Share0.030.1%0.020.0%0.030.1%0.160.3%0.160.3%
Usd Price Per Share6.23-5.31-7.06-8.85-8.85-
Price to Earnings Ratio50.65--1.10-10.07-25.74-25.74-
Price-to-Total Gains Ratio183.94--7.25--6.69-86.66-86.66-
Price to Book Ratio2.71-2.35-3.03-4.15-4.15-
Price-to-Total Gains Ratio183.94--7.25--6.69-86.66-86.66-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share6.910524
Number of shares144
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.02
Usd Book Value Change Per Share0.020.14
Usd Total Gains Per Share0.020.16
Gains per Quarter (144 shares)2.3523.52
Gains per Year (144 shares)9.4194.08
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
109-1118384
2019823166178
30281734248272
40382645331366
50473557414460
60564468497554
70665379579648
80756291662742
908571102745836
1009480113828930

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share3.01.00.075.0%9.03.00.075.0%13.03.00.081.3%13.03.00.081.3%13.03.00.081.3%
Book Value Change Per Share3.01.00.075.0%8.04.00.066.7%12.04.00.075.0%12.04.00.075.0%12.04.00.075.0%
Dividend per Share0.00.04.00.0%8.00.04.066.7%11.00.05.068.8%11.00.05.068.8%11.00.05.068.8%
Total Gains per Share3.01.00.075.0%9.03.00.075.0%13.03.00.081.3%13.03.00.081.3%13.03.00.081.3%

Fundamentals of Gan & Lee Pharmaceuticals Co Ltd

About Gan & Lee Pharmaceuticals Co Ltd

Gan & Lee Pharmaceuticals., a biopharmaceutical company, engages in the research, development, production, and sale of insulin analog active pharmaceutical ingredients (APIs) and injections in China. The company's products include Basalin, an insulin glargine injection; Prandilin, an insulin lispro and lispro mix 75/25 injection; Prandilin 25, an insulin lispro injection; Rapilin, an insulin aspart injection; Rapilin 30, an insulin aspart 30 injection; and Similin 30, an insulin injection. It also offers GanleePen, an insulin injection device; GanleeFine, an insulin pen needle; and medical devices. The company was formerly known as Beijing Gan & Lee Biotechnology Co., Ltd. and changed its name to Gan & Lee Pharmaceuticals. in April 2005. Gan & Lee Pharmaceuticals. was founded in 1998 and is headquartered in Beijing, the People's Republic of China.

Fundamental data was last updated by Penke on 2024-04-18 11:13:04.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a profit.
Using its assets, the company is inefficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Gan & Lee Pharmaceuticals Co Ltd.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Gan & Lee Pharmaceuticals Co Ltd earns for each ¥1 of revenue.

  • Above 10% is considered healthy but always compare Gan & Lee Pharmaceuticals Co Ltd to the Medical Instruments & Supplies industry mean.
  • A Net Profit Margin of 19.6% means that ¥0.20 for each ¥1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Gan & Lee Pharmaceuticals Co Ltd:

  • The MRQ is 19.6%. The company is making a huge profit. +2
  • The TTM is 8.9%. The company is making a profit. +1
Trends
Current periodCompared to+/- 
MRQ19.6%TTM8.9%+10.7%
TTM8.9%YOY-49.9%+58.8%
TTM8.9%5Y7.7%+1.2%
5Y7.7%10Y7.7%0.0%
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
MRQ19.6%6.0%+13.6%
TTM8.9%6.5%+2.4%
YOY-49.9%8.0%-57.9%
5Y7.7%7.2%+0.5%
10Y7.7%6.8%+0.9%
1.1.2. Return on Assets

Shows how efficient Gan & Lee Pharmaceuticals Co Ltd is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Gan & Lee Pharmaceuticals Co Ltd to the Medical Instruments & Supplies industry mean.
  • 1.2% Return on Assets means that Gan & Lee Pharmaceuticals Co Ltd generated ¥0.01 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Gan & Lee Pharmaceuticals Co Ltd:

  • The MRQ is 1.2%. Using its assets, the company is less efficient in making profit.
  • The TTM is 0.6%. Using its assets, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ1.2%TTM0.6%+0.7%
TTM0.6%YOY0.3%+0.2%
TTM0.6%5Y2.2%-1.6%
5Y2.2%10Y2.2%0.0%
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
MRQ1.2%1.3%-0.1%
TTM0.6%1.3%-0.7%
YOY0.3%1.8%-1.5%
5Y2.2%2.1%+0.1%
10Y2.2%2.0%+0.2%
1.1.3. Return on Equity

Shows how efficient Gan & Lee Pharmaceuticals Co Ltd is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Gan & Lee Pharmaceuticals Co Ltd to the Medical Instruments & Supplies industry mean.
  • 1.3% Return on Equity means Gan & Lee Pharmaceuticals Co Ltd generated ¥0.01 for each ¥1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Gan & Lee Pharmaceuticals Co Ltd:

  • The MRQ is 1.3%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 0.6%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ1.3%TTM0.6%+0.7%
TTM0.6%YOY0.4%+0.3%
TTM0.6%5Y2.3%-1.7%
5Y2.3%10Y2.3%0.0%
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
MRQ1.3%2.4%-1.1%
TTM0.6%2.7%-2.1%
YOY0.4%3.7%-3.3%
5Y2.3%3.8%-1.5%
10Y2.3%3.7%-1.4%

1.2. Operating Efficiency of Gan & Lee Pharmaceuticals Co Ltd.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Gan & Lee Pharmaceuticals Co Ltd is operating .

  • Measures how much profit Gan & Lee Pharmaceuticals Co Ltd makes for each ¥1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Gan & Lee Pharmaceuticals Co Ltd to the Medical Instruments & Supplies industry mean.
  • An Operating Margin of 0.0% means the company generated ¥0.00  for each ¥1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Gan & Lee Pharmaceuticals Co Ltd:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-9.0%+9.0%
TTM-9.0%YOY-68.0%+59.0%
TTM-9.0%5Y0.7%-9.7%
5Y0.7%10Y0.7%0.0%
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
MRQ-8.1%-8.1%
TTM-9.0%7.6%-16.6%
YOY-68.0%10.9%-78.9%
5Y0.7%10.1%-9.4%
10Y0.7%10.5%-9.8%
1.2.2. Operating Ratio

Measures how efficient Gan & Lee Pharmaceuticals Co Ltd is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Medical Instruments & Supplies industry mean).
  • An Operation Ratio of 1.05 means that the operating costs are ¥1.05 for each ¥1 in net sales.

Let's take a look of the Operating Ratio trends of Gan & Lee Pharmaceuticals Co Ltd:

  • The MRQ is 1.046. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.261. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.046TTM1.261-0.215
TTM1.261YOY1.925-0.665
TTM1.2615Y1.146+0.115
5Y1.14610Y1.1460.000
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
MRQ1.0461.143-0.097
TTM1.2611.168+0.093
YOY1.9251.105+0.820
5Y1.1461.097+0.049
10Y1.1461.063+0.083

1.3. Liquidity of Gan & Lee Pharmaceuticals Co Ltd.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Gan & Lee Pharmaceuticals Co Ltd is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Medical Instruments & Supplies industry mean).
  • A Current Ratio of 7.65 means the company has ¥7.65 in assets for each ¥1 in short-term debts.

Let's take a look of the Current Ratio trends of Gan & Lee Pharmaceuticals Co Ltd:

  • The MRQ is 7.647. The company is very able to pay all its short-term debts. +2
  • The TTM is 7.376. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ7.647TTM7.376+0.271
TTM7.376YOY14.286-6.910
TTM7.3765Y11.528-4.152
5Y11.52810Y11.5280.000
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
MRQ7.6472.310+5.337
TTM7.3762.358+5.018
YOY14.2862.614+11.672
5Y11.5282.649+8.879
10Y11.5282.630+8.898
1.3.2. Quick Ratio

Measures if Gan & Lee Pharmaceuticals Co Ltd is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Gan & Lee Pharmaceuticals Co Ltd to the Medical Instruments & Supplies industry mean.
  • A Quick Ratio of 3.45 means the company can pay off ¥3.45 for each ¥1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Gan & Lee Pharmaceuticals Co Ltd:

  • The MRQ is 3.450. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 2.640. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ3.450TTM2.640+0.810
TTM2.640YOY4.761-2.121
TTM2.6405Y3.986-1.346
5Y3.98610Y3.9860.000
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
MRQ3.4501.119+2.331
TTM2.6401.148+1.492
YOY4.7611.306+3.455
5Y3.9861.433+2.553
10Y3.9861.544+2.442

1.4. Solvency of Gan & Lee Pharmaceuticals Co Ltd.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Gan & Lee Pharmaceuticals Co Ltd assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Gan & Lee Pharmaceuticals Co Ltd to Medical Instruments & Supplies industry mean.
  • A Debt to Asset Ratio of 0.09 means that Gan & Lee Pharmaceuticals Co Ltd assets are financed with 8.6% credit (debt) and the remaining percentage (100% - 8.6%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Gan & Lee Pharmaceuticals Co Ltd:

  • The MRQ is 0.086. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.091. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.086TTM0.091-0.005
TTM0.091YOY0.064+0.027
TTM0.0915Y0.073+0.018
5Y0.07310Y0.0730.000
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0860.351-0.265
TTM0.0910.357-0.266
YOY0.0640.349-0.285
5Y0.0730.359-0.286
10Y0.0730.369-0.296
1.4.2. Debt to Equity Ratio

Measures if Gan & Lee Pharmaceuticals Co Ltd is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Gan & Lee Pharmaceuticals Co Ltd to the Medical Instruments & Supplies industry mean.
  • A Debt to Equity ratio of 9.4% means that company has ¥0.09 debt for each ¥1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Gan & Lee Pharmaceuticals Co Ltd:

  • The MRQ is 0.094. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.100. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.094TTM0.100-0.006
TTM0.100YOY0.068+0.032
TTM0.1005Y0.079+0.021
5Y0.07910Y0.0790.000
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0940.541-0.447
TTM0.1000.552-0.452
YOY0.0680.545-0.477
5Y0.0790.632-0.553
10Y0.0790.669-0.590

2. Market Valuation of Gan & Lee Pharmaceuticals Co Ltd

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ¥1 in earnings Gan & Lee Pharmaceuticals Co Ltd generates.

  • Above 15 is considered overpriced but always compare Gan & Lee Pharmaceuticals Co Ltd to the Medical Instruments & Supplies industry mean.
  • A PE ratio of 50.65 means the investor is paying ¥50.65 for every ¥1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Gan & Lee Pharmaceuticals Co Ltd:

  • The EOD is 56.174. Based on the earnings, the company is expensive. -2
  • The MRQ is 50.651. Based on the earnings, the company is expensive. -2
  • The TTM is -1.099. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD56.174MRQ50.651+5.523
MRQ50.651TTM-1.099+51.750
TTM-1.099YOY10.074-11.174
TTM-1.0995Y25.739-26.838
5Y25.73910Y25.7390.000
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
EOD56.17414.883+41.291
MRQ50.65115.934+34.717
TTM-1.09916.048-17.147
YOY10.07420.784-10.710
5Y25.73920.830+4.909
10Y25.73922.810+2.929
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Gan & Lee Pharmaceuticals Co Ltd:

  • The EOD is -49.749. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -44.858. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -35.027. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-49.749MRQ-44.858-4.891
MRQ-44.858TTM-35.027-9.831
TTM-35.027YOY21.318-56.344
TTM-35.0275Y-7.138-27.889
5Y-7.13810Y-7.1380.000
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
EOD-49.7496.933-56.682
MRQ-44.8587.358-52.216
TTM-35.0270.019-35.046
YOY21.3183.922+17.396
5Y-7.1388.172-15.310
10Y-7.1380.247-7.385
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Gan & Lee Pharmaceuticals Co Ltd is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Medical Instruments & Supplies industry mean).
  • A PB ratio of 2.71 means the investor is paying ¥2.71 for each ¥1 in book value.

Let's take a look of the Price to Book Ratio trends of Gan & Lee Pharmaceuticals Co Ltd:

  • The EOD is 3.006. Based on the equity, the company is fair priced.
  • The MRQ is 2.711. Based on the equity, the company is underpriced. +1
  • The TTM is 2.349. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD3.006MRQ2.711+0.296
MRQ2.711TTM2.349+0.361
TTM2.349YOY3.033-0.684
TTM2.3495Y4.145-1.796
5Y4.14510Y4.1450.000
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
EOD3.0062.405+0.601
MRQ2.7112.753-0.042
TTM2.3492.660-0.311
YOY3.0333.303-0.270
5Y4.1453.958+0.187
10Y4.1454.277-0.132
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Gan & Lee Pharmaceuticals Co Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.2450.118+107%0.011+2132%1.040-76%1.040-76%
Book Value Per Share--16.64616.353+2%16.779-1%15.059+11%15.059+11%
Current Ratio--7.6477.376+4%14.286-46%11.528-34%11.528-34%
Debt To Asset Ratio--0.0860.091-5%0.064+35%0.073+19%0.073+19%
Debt To Equity Ratio--0.0940.100-6%0.068+39%0.079+20%0.079+20%
Dividend Per Share----0%0.208-100%0.142-100%0.142-100%
Eps--0.2230.116+91%0.070+216%0.321-31%0.321-31%
Free Cash Flow Per Share---0.251-0.362+44%-0.046-82%-0.007-97%-0.007-97%
Free Cash Flow To Equity Per Share---0.251-0.334+33%-0.118-53%0.483-152%0.483-152%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---34.247--------
Intrinsic Value_10Y_min---28.555--------
Intrinsic Value_1Y_max---0.808--------
Intrinsic Value_1Y_min---0.792--------
Intrinsic Value_3Y_max---4.428--------
Intrinsic Value_3Y_min---4.187--------
Intrinsic Value_5Y_max---10.458--------
Intrinsic Value_5Y_min---9.535--------
Market Cap29731865679.360+10%26808588718.08022852955309.600+17%30380987646.880-12%38089868038.040-30%38089868038.040-30%
Net Profit Margin--0.1960.089+120%-0.499+355%0.077+153%0.077+153%
Operating Margin----0.0900%-0.6800%0.007-100%0.007-100%
Operating Ratio--1.0461.261-17%1.925-46%1.146-9%1.146-9%
Pb Ratio3.006+10%2.7112.349+15%3.033-11%4.145-35%4.145-35%
Pe Ratio56.174+10%50.651-1.099+102%10.074+403%25.739+97%25.739+97%
Price Per Share50.040+10%45.12038.463+17%51.133-12%64.107-30%64.107-30%
Price To Free Cash Flow Ratio-49.749-11%-44.858-35.027-22%21.318-310%-7.138-84%-7.138-84%
Price To Total Gains Ratio204.001+10%183.943-7.249+104%-6.687+104%86.661+112%86.661+112%
Quick Ratio--3.4502.640+31%4.761-28%3.986-13%3.986-13%
Return On Assets--0.0120.006+119%0.003+267%0.022-44%0.022-44%
Return On Equity--0.0130.006+118%0.004+282%0.023-43%0.023-43%
Total Gains Per Share--0.2450.118+107%0.219+12%1.183-79%1.183-79%
Usd Book Value--1365870271.6641341851440.987+2%1376769838.578-1%1235648428.355+11%1235648428.355+11%
Usd Book Value Change Per Share--0.0340.016+107%0.002+2132%0.144-76%0.144-76%
Usd Book Value Per Share--2.2992.258+2%2.317-1%2.080+11%2.080+11%
Usd Dividend Per Share----0%0.029-100%0.020-100%0.020-100%
Usd Eps--0.0310.016+91%0.010+216%0.044-31%0.044-31%
Usd Free Cash Flow---20633293.791-29665561.244+44%-3736573.316-82%-563081.577-97%-563081.577-97%
Usd Free Cash Flow Per Share---0.035-0.050+44%-0.006-82%-0.001-97%-0.001-97%
Usd Free Cash Flow To Equity Per Share---0.035-0.046+33%-0.016-53%0.067-152%0.067-152%
Usd Market Cap4105970650.320+10%3702266101.9673155993128.256+17%4195614394.034-12%5260210776.053-30%5260210776.053-30%
Usd Price Per Share6.911+10%6.2315.312+17%7.061-12%8.853-30%8.853-30%
Usd Profit--18273480.1048312426.816+120%5784264.885+216%26033764.458-30%26033764.458-30%
Usd Revenue--93342586.01182205815.798+14%80990760.470+15%100412845.466-7%100412845.466-7%
Usd Total Gains Per Share--0.0340.016+107%0.030+12%0.163-79%0.163-79%
 EOD+5 -3MRQTTM+29 -3YOY+16 -185Y+9 -2610Y+9 -26

3.2. Fundamental Score

Let's check the fundamental score of Gan & Lee Pharmaceuticals Co Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1556.174
Price to Book Ratio (EOD)Between0-13.006
Net Profit Margin (MRQ)Greater than00.196
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than13.450
Current Ratio (MRQ)Greater than17.647
Debt to Asset Ratio (MRQ)Less than10.086
Debt to Equity Ratio (MRQ)Less than10.094
Return on Equity (MRQ)Greater than0.150.013
Return on Assets (MRQ)Greater than0.050.012
Total5/10 (50.0%)

3.3. Technical Score

Let's check the technical score of Gan & Lee Pharmaceuticals Co Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5068.379
Ma 20Greater thanMa 5045.335
Ma 50Greater thanMa 10043.274
Ma 100Greater thanMa 20045.485
OpenGreater thanClose49.300
Total3/5 (60.0%)



Latest Balance Sheet

Balance Sheet of 2023-09-30. Currency in CNY. All numbers in thousands.

Summary
Total Assets10,825,038
Total Liabilities934,594
Total Stockholder Equity9,890,606
 As reported
Total Liabilities 934,594
Total Stockholder Equity+ 9,890,606
Total Assets = 10,825,038

Assets

Total Assets10,825,038
Total Current Assets5,488,181
Long-term Assets5,336,856
Total Current Assets
Cash And Cash Equivalents 2,093,406
Short-term Investments 2,077,608
Net Receivables 398,288
Inventory 858,848
Other Current Assets 1,964
Total Current Assets  (as reported)5,488,181
Total Current Assets  (calculated)5,430,115
+/- 58,067
Long-term Assets
Property Plant Equipment 3,716,821
Intangible Assets 1,076,077
Long-term Assets Other 93,028
Long-term Assets  (as reported)5,336,856
Long-term Assets  (calculated)4,885,925
+/- 450,931

Liabilities & Shareholders' Equity

Total Current Liabilities717,656
Long-term Liabilities216,938
Total Stockholder Equity9,890,606
Total Current Liabilities
Accounts payable 89,744
Other Current Liabilities 158
Total Current Liabilities  (as reported)717,656
Total Current Liabilities  (calculated)89,903
+/- 627,753
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt8,180
Long-term Liabilities  (as reported)216,938
Long-term Liabilities  (calculated)8,180
+/- 208,758
Total Stockholder Equity
Retained Earnings 6,500,012
Total Stockholder Equity (as reported)9,890,606
Total Stockholder Equity (calculated)6,500,012
+/- 3,390,594
Other
Capital Stock565,653
Common Stock Shares Outstanding 565,653
Net Invested Capital 9,890,606
Net Working Capital 4,770,526
Property Plant and Equipment Gross 3,716,821



Balance Sheet

Currency in CNY. All numbers in thousands.

 Trend2023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-31
> Total Assets 
6,026,681
6,004,085
8,735,698
9,030,488
9,507,449
9,647,481
9,841,484
10,256,418
10,853,163
10,917,097
10,417,969
10,400,422
10,606,912
10,595,877
10,729,143
10,825,038
10,825,03810,729,14310,595,87710,606,91210,400,42210,417,96910,917,09710,853,16310,256,4189,841,4849,647,4819,507,4499,030,4888,735,6986,004,0856,026,681
   > Total Current Assets 
3,110,098
3,141,850
5,536,421
5,662,331
5,959,614
5,885,157
6,003,605
6,365,759
6,870,443
6,774,616
6,190,971
5,840,097
5,664,136
5,624,401
5,712,582
5,488,181
5,488,1815,712,5825,624,4015,664,1365,840,0976,190,9716,774,6166,870,4436,365,7596,003,6055,885,1575,959,6145,662,3315,536,4213,141,8503,110,098
       Cash And Cash Equivalents 
483,217
494,256
3,019,708
2,429,867
2,824,812
2,789,750
3,012,532
3,100,284
3,305,708
3,390,761
3,272,324
2,960,588
2,890,267
2,743,914
3,062,691
2,093,406
2,093,4063,062,6912,743,9142,890,2672,960,5883,272,3243,390,7613,305,7083,100,2843,012,5322,789,7502,824,8122,429,8673,019,708494,256483,217
       Short-term Investments 
1,058,272
1,251,658
1,200,174
1,435,121
787,050
1,144,504
1,098,104
1,203,256
1,624,183
1,556,255
1,466,003
1,817,257
1,635,950
1,648,613
1,533,987
2,077,608
2,077,6081,533,9871,648,6131,635,9501,817,2571,466,0031,556,2551,624,1831,203,2561,098,1041,144,504787,0501,435,1211,200,1741,251,6581,058,272
       Net Receivables 
843,897
551,414
423,367
565,773
832,347
597,019
688,887
726,812
941,151
750,606
331,200
135,954
190,553
206,154
313,337
398,288
398,288313,337206,154190,553135,954331,200750,606941,151726,812688,887597,019832,347565,773423,367551,414843,897
       Inventory 
471,349
501,544
527,862
525,583
493,482
560,444
578,063
575,548
651,329
732,290
732,718
668,230
648,646
688,682
749,457
858,848
858,848749,457688,682648,646668,230732,718732,290651,329575,548578,063560,444493,482525,583527,862501,544471,349
       Other Current Assets 
203,468
82,273
53,498
705,987
76,583
743,441
78,672
486,037
348,072
344,704
75,911
56,725
97,362
254,321
53,040
1,964
1,96453,040254,32197,36256,72575,911344,704348,072486,03778,672743,44176,583705,98753,49882,273203,468
   > Long-term Assets 
2,916,583
2,862,235
3,199,277
3,368,156
3,547,835
3,762,323
3,837,879
3,890,659
3,982,720
4,142,482
4,226,997
4,560,325
4,942,776
4,971,476
5,016,561
5,336,856
5,336,8565,016,5614,971,4764,942,7764,560,3254,226,9974,142,4823,982,7203,890,6593,837,8793,762,3233,547,8353,368,1563,199,2772,862,2352,916,583
       Property Plant Equipment 
0
1,883,660
1,930,537
2,025,374
2,149,002
2,219,312
2,504,630
2,579,025
2,595,370
2,638,127
2,818,112
3,050,526
3,661,337
3,669,036
3,709,363
3,716,821
3,716,8213,709,3633,669,0363,661,3373,050,5262,818,1122,638,1272,595,3702,579,0252,504,6302,219,3122,149,0022,025,3741,930,5371,883,6600
       Intangible Assets 
591,334
608,077
737,446
746,646
769,623
773,957
790,878
799,236
872,485
913,382
939,567
1,002,621
1,026,043
1,049,572
1,072,131
1,076,077
1,076,0771,072,1311,049,5721,026,0431,002,621939,567913,382872,485799,236790,878773,957769,623746,646737,446608,077591,334
       Long-term Assets Other 
419,579
355,594
516,854
2,607,520
600,713
730,292
502,452
473,660
240,326
309,239
386,602
409,797
76,513
82,839
81,119
93,028
93,02881,11982,83976,513409,797386,602309,239240,326473,660502,452730,292600,7132,607,520516,854355,594419,579
> Total Liabilities 
555,883
409,230
515,273
634,236
569,091
519,373
757,172
673,233
686,021
631,717
602,319
791,119
1,021,273
950,580
984,444
934,594
934,594984,444950,5801,021,273791,119602,319631,717686,021673,233757,172519,373569,091634,236515,273409,230555,883
   > Total Current Liabilities 
458,221
320,179
437,903
510,932
409,850
311,436
561,735
476,914
485,531
414,044
381,970
560,362
813,037
743,706
779,615
717,656
717,656779,615743,706813,037560,362381,970414,044485,531476,914561,735311,436409,850510,932437,903320,179458,221
       Accounts payable 
30,650
17,224
30,754
20,971
14,794
17,907
28,714
30,350
37,741
33,797
38,042
58,156
41,456
86,499
87,638
89,744
89,74487,63886,49941,45658,15638,04233,79737,74130,35028,71417,90714,79420,97130,75417,22430,650
       Other Current Liabilities 
38,372
218,254
270,301
393,585
274,151
207,277
363,750
321,791
303,947
233,815
201,750
344,099
575,899
613
499,418
158
158499,418613575,899344,099201,750233,815303,947321,791363,750207,277274,151393,585270,301218,25438,372
   > Long-term Liabilities 
97,662
89,051
77,371
123,304
159,241
207,937
195,437
196,319
200,490
217,673
220,349
230,758
208,236
206,873
204,829
216,938
216,938204,829206,873208,236230,758220,349217,673200,490196,319195,437207,937159,241123,30477,37189,05197,662
       Long term Debt 
683
2,238
2,281
2,142
0
0
0
0
0
0
0
0
0
0
0
0
0000000000002,1422,2812,238683
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
0
14,881
14,546
13,761
12,166
13,044
13,247
13,423
8,327
8,066
8,526
8,180
8,1808,5268,0668,32713,42313,24713,04412,16613,76114,54614,88100000
       Other Liabilities 
0
89,051
77,370
123,304
159,241
193,057
180,891
182,558
188,324
204,630
207,103
217,334
199,909
0
196,303
0
0196,3030199,909217,334207,103204,630188,324182,558180,891193,057159,241123,30477,37089,0510
       Long-term Liabilities Other 
0
0
0
0
0
1,459
0
1,031
0
10,159
0
0
0
0
0
0
00000010,15901,03101,45900000
       Deferred Long Term Liability 
0
492,369
524,369
522,552
544,275
537,582
556,767
545,641
588,873
635,659
663,085
720,235
743,195
0
798,589
0
0798,5890743,195720,235663,085635,659588,873545,641556,767537,582544,275522,552524,369492,3690
> Total Stockholder Equity
5,470,960
5,595,017
8,220,587
8,396,414
8,938,520
9,128,270
9,084,474
9,583,347
10,167,305
10,285,543
9,815,812
9,609,466
9,585,802
9,645,460
9,744,862
9,890,606
9,890,6069,744,8629,645,4609,585,8029,609,4669,815,81210,285,54310,167,3059,583,3479,084,4749,128,2708,938,5208,396,4148,220,5875,595,0175,470,960
   Common Stock
0
360,900
401,100
561,540
561,540
561,540
561,540
561,540
561,540
561,540
561,540
561,540
565,653
0
565,653
0
0565,6530565,653561,540561,540561,540561,540561,540561,540561,540561,540561,540401,100360,9000
   Retained Earnings 
4,743,655
5,158,299
5,342,835
5,360,402
5,904,908
6,094,986
6,053,062
6,551,702
7,133,047
7,246,344
6,766,978
6,550,779
6,525,068
6,282,760
6,659,224
6,500,012
6,500,0126,659,2246,282,7606,525,0686,550,7796,766,9787,246,3447,133,0476,551,7026,053,0626,094,9865,904,9085,360,4025,342,8355,158,2994,743,655
   Capital Surplus 0000000000000000
   Treasury Stock0000000000000000
   Other Stockholders Equity 
0
3,129
3,029
848
-1,551
-1,879
26,791
-3,519
-3,440
-3,756
567
5,134
3,442
0
81,017
0
081,01703,4425,134567-3,756-3,440-3,51926,791-1,879-1,5518483,0293,1290



Balance Sheet

Currency in CNY. All numbers in thousands.




Cash Flow

Currency in CNY. All numbers in thousands.




Income Statement

Currency in CNY. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue2,381,052
Cost of Revenue-616,234
Gross Profit1,764,8181,764,818
 
Operating Income (+$)
Gross Profit1,764,818
Operating Expense-2,321,567
Operating Income59,485-556,749
 
Operating Expense (+$)
Research Development539,212
Selling General Administrative1,006,774
Selling And Marketing Expenses-
Operating Expense2,321,5671,545,985
 
Net Interest Income (+$)
Interest Income-
Interest Expense--
Other Finance Cost-93,360
Net Interest Income93,360
 
Pretax Income (+$)
Operating Income59,485
Net Interest Income93,360
Other Non-Operating Income Expenses-
Income Before Tax (EBT)161,45359,485
EBIT - interestExpense = 0
240,765
240,765
Interest Expense-
Earnings Before Interest and Taxes (EBIT)-161,453
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax161,453
Tax Provision--79,312
Net Income From Continuing Ops240,765240,765
Net Income240,765
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net--93,360
 

Technical Analysis of Gan & Lee Pharmaceuticals Co Ltd
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Gan & Lee Pharmaceuticals Co Ltd. The general trend of Gan & Lee Pharmaceuticals Co Ltd is BULLISH with 42.9% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Gan & Lee Pharmaceuticals Co Ltd's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (42.9%) Bearish trend (-42.9%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Gan & Lee Pharmaceuticals Co Ltd.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 50.31 < 54.00 < 62.90.

The bearish price targets are: 47.50 > 41.29 > 39.12.

Tweet this
Gan & Lee Pharmaceuticals Co Ltd Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Gan & Lee Pharmaceuticals Co Ltd. The current mas is .

The long score for the Moving Averages is 10/14.
The longshort score for the Moving Averages is 6/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Gan & Lee Pharmaceuticals Co Ltd Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Gan & Lee Pharmaceuticals Co Ltd. The current macd is 1.75099397.

The long score for the Moving Average Convergence/Divergence (MACD) is 4/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 4/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Gan & Lee Pharmaceuticals Co Ltd price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Gan & Lee Pharmaceuticals Co Ltd. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Gan & Lee Pharmaceuticals Co Ltd price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Gan & Lee Pharmaceuticals Co Ltd Daily Moving Average Convergence/Divergence (MACD) ChartGan & Lee Pharmaceuticals Co Ltd Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Gan & Lee Pharmaceuticals Co Ltd. The current adx is 29.33.

The long score for the Directional Movement Index (DMI) is 4/7.
The longshort score for the Directional Movement Index (DMI) is 4/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Gan & Lee Pharmaceuticals Co Ltd shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bullish trend. The ADX is trending up, so the bullish trend is strengthening.
Gan & Lee Pharmaceuticals Co Ltd Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Gan & Lee Pharmaceuticals Co Ltd. The current sar is 42.74.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Gan & Lee Pharmaceuticals Co Ltd Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Gan & Lee Pharmaceuticals Co Ltd. The current rsi is 68.38. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending up: The RSI is trending up. +1
Gan & Lee Pharmaceuticals Co Ltd Daily Relative Strength Index (RSI) ChartGan & Lee Pharmaceuticals Co Ltd Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Gan & Lee Pharmaceuticals Co Ltd. The current phase is Continuation in bull market.

The long score for the Stochastic Oscillator is 1/6.
The longshort score for the Stochastic Oscillator is -2/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Gan & Lee Pharmaceuticals Co Ltd price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Gan & Lee Pharmaceuticals Co Ltd Daily Stochastic Oscillator ChartGan & Lee Pharmaceuticals Co Ltd Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Gan & Lee Pharmaceuticals Co Ltd. The current cci is 158.56.

The long score for the Commodity Channel Index (CCI) is 1/1.
The longshort score for the Commodity Channel Index (CCI) is 1/(-1 +1).

  • CCI > 100: The CCI is above 100, it indicates that the price is significantly above its average, suggesting a potential overbought condition. +1
Gan & Lee Pharmaceuticals Co Ltd Daily Commodity Channel Index (CCI) ChartGan & Lee Pharmaceuticals Co Ltd Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Gan & Lee Pharmaceuticals Co Ltd. The current cmo is 46.97.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Gan & Lee Pharmaceuticals Co Ltd Daily Chande Momentum Oscillator (CMO) ChartGan & Lee Pharmaceuticals Co Ltd Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Gan & Lee Pharmaceuticals Co Ltd. The current willr is -20.52679382.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Gan & Lee Pharmaceuticals Co Ltd is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Gan & Lee Pharmaceuticals Co Ltd Daily Williams %R ChartGan & Lee Pharmaceuticals Co Ltd Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Gan & Lee Pharmaceuticals Co Ltd.

Gan & Lee Pharmaceuticals Co Ltd Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Gan & Lee Pharmaceuticals Co Ltd. The current atr is 1.9914404.

Gan & Lee Pharmaceuticals Co Ltd Daily Average True Range (ATR) ChartGan & Lee Pharmaceuticals Co Ltd Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Gan & Lee Pharmaceuticals Co Ltd. The current obv is 190,803,408.

Gan & Lee Pharmaceuticals Co Ltd Daily On-Balance Volume (OBV) ChartGan & Lee Pharmaceuticals Co Ltd Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Gan & Lee Pharmaceuticals Co Ltd. The current mfi is 69.18.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Gan & Lee Pharmaceuticals Co Ltd Daily Money Flow Index (MFI) ChartGan & Lee Pharmaceuticals Co Ltd Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Gan & Lee Pharmaceuticals Co Ltd.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-01BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-04WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-05BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-06STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-07RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-08SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-12-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-14STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-15WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-21STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-25STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-29SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-01-02STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-04DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-05STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-08BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-10STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-15STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-17STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-22STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-24STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-26STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-29CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-05STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-02-06RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-07SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-20WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-23DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-02-26STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-29WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-06CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-07SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-08WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-11STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-14SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-22CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-25MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-27BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-28STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-29WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-01DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-02MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-03STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-08ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-17CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-18MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-22CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-23MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-25STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-26STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-04-30STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

Gan & Lee Pharmaceuticals Co Ltd Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Gan & Lee Pharmaceuticals Co Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5068.379
Ma 20Greater thanMa 5045.335
Ma 50Greater thanMa 10043.274
Ma 100Greater thanMa 20045.485
OpenGreater thanClose49.300
Total3/5 (60.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Gan & Lee Pharmaceuticals Co Ltd with someone you think should read this too:
  • Are you bullish or bearish on Gan & Lee Pharmaceuticals Co Ltd? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Gan & Lee Pharmaceuticals Co Ltd? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Gan & Lee Pharmaceuticals Co Ltd

I send you an email if I find something interesting about Gan & Lee Pharmaceuticals Co Ltd.


Comments

How you think about this?

Leave a comment

Stay informed about Gan & Lee Pharmaceuticals Co Ltd.

Receive notifications about Gan & Lee Pharmaceuticals Co Ltd in your mailbox!